SMT’s Hydra TAVR Valve Demonstrates Sustained Safety, Durability, and Hemodynamic Performance at 5 Years
19th November 2025 , Mumbai- Sahajanand Medical Technologies’ (SMT) TAVR product Hydra’s 5-year follow-up results from the pivotal Hydra CE Study were presented by Dr. Vilhelmas Bajoras at PCR London Valves 2025. The long-term data reaffirm Hydra’s durable valve performance, sustained hemodynamic improvement, and favourable safety profile in patients with severe aortic stenosis. The Hydra CE Study, led by Prof. Audrius Aidietis (Vilnius University Hospital Santaros Clinics, Lithuania) and Prof. Adam Witkowski (National Institute of Cardiology, Warsaw, Poland), was a prospective, multicenter clinical trial that enrolled 157 patients across Europe. Of these, 54 patients from Lithuania and Poland were followed for up to 5 years, providing valuable long-term evidence on valve durability and clinical outcomes. At 5 years, Hydra demonstrated high overall survival, low rates of disabling stroke, and durable valve performance with stable gradients and effective orifice area. Im...